MedTrace Logo

AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

NCT02102165 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2025-07-16

No results posted yet for this study

Summary

This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer.

In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.

Conditions

Interventions

PROCEDURE

metastatic lesion biopsy

a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion

Sponsors & Collaborators

  • Jules Bordet Institute

    collaborator OTHER

  • Frontier Science & Technology Research Foundation, Inc.

    collaborator INDUSTRY

  • Breast International Group

    lead OTHER

Principal Investigators

  • Philippe Aftimos, MD · Institut Jules Bordet, Brussels, Belgium

  • Angel Guerrero Zotano, MD · Instituto Valenciano de Oncologia, Valencia, Spain

  • Matteo Benelli, PhD · Breast International Group

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2027-12-31
Completion
2031-03-31

Countries

  • Belgium
  • Germany
  • Iceland
  • Italy
  • Luxembourg
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02102165 on ClinicalTrials.gov